Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs

P. David Charles, Bimal B. Padaliya, William J. Newman, Chandler E. Gill, Cassondra D. Covington, John Y. Fang, Stephanie A. So, Michael G. Tramontana, Peter E. Konrad, Thomas L. Davis

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalParkinsonism and Related Disorders
Volume10
Issue number8
DOIs
StatePublished - Dec 2004
Externally publishedYes

    Fingerprint

Keywords

  • Antiparkinsonian medications
  • Cost analysis
  • Deep brain stimulation
  • Parkinson's disease
  • Subthalamic nucleus

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology

Cite this

David Charles, P., Padaliya, B. B., Newman, W. J., Gill, C. E., Covington, C. D., Fang, J. Y., So, S. A., Tramontana, M. G., Konrad, P. E., & Davis, T. L. (2004). Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism and Related Disorders, 10(8), 475-479. https://doi.org/10.1016/j.parkreldis.2004.05.006